TrialGynecologic oncology2018

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

Panagiotis A Konstantinopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.